# Reviva Pharmaceuticals Holdings, Inc.: financial statements, quarterly

RVPH · OTC · CIK 1742927 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rvph.md) · [Financials](/companies/rvph/financials.md) · [Filings](/companies/rvph/filings.md) · [Insiders](/companies/rvph/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rvph/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [9.6](/filings/0001437749-24-035375.md) | [8.1 d](/filings/0001437749-25-010791.md) | [5.8](/filings/0001437749-25-017191.md) | [5.6](/filings/0001437749-25-026967.md) | [6.9](/filings/0001437749-25-034827.md) | [4.7 d](/filings/0001437749-26-010126.md) | [4.1](/filings/0001437749-26-016762.md) | [3.7](/filings/0001437749-26-027358.md) | [2.1](/filings/0001437749-25-034827.md) | [1.7 d](/filings/0001437749-26-010126.md) | [1.4](/filings/0001437749-26-016762.md) | [1.4](/filings/0001437749-26-027358.md) |
| Operating income | $m | [(11.6)](/filings/0001437749-24-035375.md) | [(9.6) d](/filings/0001437749-25-010791.md) | [(7.9)](/filings/0001437749-25-017191.md) | [(8.1)](/filings/0001437749-25-026967.md) | [(8.5)](/filings/0001437749-25-034827.md) | [(6.3) d](/filings/0001437749-26-010126.md) | [(6.5)](/filings/0001437749-26-016762.md) | [(6.1)](/filings/0001437749-26-027358.md) | [(4.0)](/filings/0001437749-25-034827.md) | [(3.6) d](/filings/0001437749-26-010126.md) | [(3.3)](/filings/0001437749-26-016762.md) | [(2.6)](/filings/0001437749-26-027358.md) |
| Interest expense | $m | [0.0](/filings/0001437749-23-031973.md) | [0.0 d](/filings/0001437749-25-010791.md) | [0.0](/filings/0001437749-24-016366.md) | [0.0](/filings/0001437749-25-026967.md) | [0.0](/filings/0001437749-25-034827.md) | [0.0 d](/filings/0001437749-26-010126.md) | [0.0](/filings/0001437749-26-016762.md) | [0.0](/filings/0001437749-26-027358.md) | [0.0](/filings/0001437749-25-034827.md) | [(0.0) d](/filings/0001437749-26-010126.md) | [0.0](/filings/0001437749-26-016762.md) | [0.0](/filings/0001437749-26-027358.md) |
| Income tax | $m | [0.0](/filings/0001437749-24-035375.md) | [(0.0) d](/filings/0001437749-25-010791.md) | [0.0](/filings/0001437749-25-017191.md) | [0.0](/filings/0001437749-25-026967.md) | [0.0](/filings/0001437749-25-034827.md) | [0.0 d](/filings/0001437749-26-010126.md) | [0.0](/filings/0001437749-26-016762.md) | [0.0](/filings/0001437749-26-027358.md) | [0.0](/filings/0001437749-25-034827.md) | [0.0 d](/filings/0001437749-26-010126.md) | [0.0](/filings/0001437749-26-016762.md) | [0.0](/filings/0001437749-26-027358.md) |
| Net income | $m | [(11.3)](/filings/0001437749-24-035375.md) | [(9.4) d](/filings/0001437749-25-010791.md) | [(7.4)](/filings/0001437749-25-017191.md) | [(7.9)](/filings/0001437749-25-026967.md) | [(8.4)](/filings/0001437749-25-034827.md) | [(6.3) d](/filings/0001437749-26-010126.md) | [(6.4)](/filings/0001437749-26-016762.md) | [(6.1)](/filings/0001437749-26-027358.md) | [(4.0)](/filings/0001437749-25-034827.md) | [(3.4) d](/filings/0001437749-26-010126.md) | [(3.2)](/filings/0001437749-26-016762.md) | [(2.4)](/filings/0001437749-26-027358.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(0.48)](/filings/0001437749-24-035375.md) | not reported | [(0.25)](/filings/0001437749-25-017191.md) | [(0.26)](/filings/0001437749-25-026967.md) | [(0.25)](/filings/0001437749-25-034827.md) | not reported | [(2.61)](/filings/0001437749-26-016762.md) | [(2.40)](/filings/0001437749-26-027358.md) | [(0.06)](/filings/0001437749-25-034827.md) | not reported | [(0.46)](/filings/0001437749-26-016762.md) | [(0.19)](/filings/0001437749-26-027358.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [5.0](/filings/0001437749-23-031973.md) | [23.4](/filings/0001437749-25-010791.md) | [12.0](/filings/0001437749-24-016366.md) | [6.2](/filings/0001437749-24-026571.md) | [5.6](/filings/0001437749-24-035375.md) | [13.5](/filings/0001437749-26-010126.md) | [5.3](/filings/0001437749-25-017191.md) | [10.4](/filings/0001437749-25-026967.md) | [13.2](/filings/0001437749-25-034827.md) | [14.4](/filings/0001437749-26-027358.md) | [22.2](/filings/0001437749-26-016762.md) | [19.9](/filings/0001437749-26-027358.md) |
| Current assets | $m | not reported | [23.7](/filings/0001437749-25-010791.md) | not reported | [7.2](/filings/0001437749-24-026571.md) | [6.8](/filings/0001437749-24-035375.md) | [14.7](/filings/0001437749-26-010126.md) | [6.3](/filings/0001437749-25-017191.md) | [10.8](/filings/0001437749-25-026967.md) | [13.5](/filings/0001437749-25-034827.md) | [15.1](/filings/0001437749-26-027358.md) | [23.6](/filings/0001437749-26-016762.md) | [21.1](/filings/0001437749-26-027358.md) |
| Total assets | $m | [5.4](/filings/0001437749-23-031973.md) | [23.7](/filings/0001437749-25-010791.md) | [13.5](/filings/0001437749-24-016366.md) | [8.1](/filings/0001437749-24-026571.md) | [7.6](/filings/0001437749-24-035375.md) | [15.5](/filings/0001437749-26-010126.md) | [7.1](/filings/0001437749-25-017191.md) | [11.6](/filings/0001437749-25-026967.md) | [14.3](/filings/0001437749-25-034827.md) | [15.9](/filings/0001437749-26-027358.md) | [23.6](/filings/0001437749-26-016762.md) | [21.1](/filings/0001437749-26-027358.md) |
| Current liabilities | $m | [17.3](/filings/0001437749-24-011955.md) | [17.2](/filings/0001437749-25-010791.md) | [14.5](/filings/0001437749-24-016366.md) | [13.9](/filings/0001437749-24-026571.md) | [17.5](/filings/0001437749-24-035375.md) | [14.6](/filings/0001437749-26-010126.md) | [11.5](/filings/0001437749-25-017191.md) | [12.1](/filings/0001437749-25-026967.md) | [9.7](/filings/0001437749-25-034827.md) | [7.3](/filings/0001437749-26-027358.md) | [6.1](/filings/0001437749-26-016762.md) | [5.9](/filings/0001437749-26-027358.md) |
| Total liabilities | $m | [18.2](/filings/0001437749-24-011955.md) | [18.0](/filings/0001437749-25-010791.md) | [14.8](/filings/0001437749-24-016366.md) | [14.1](/filings/0001437749-24-026571.md) | [17.6](/filings/0001437749-24-035375.md) | [14.7](/filings/0001437749-26-010126.md) | [11.5](/filings/0001437749-25-017191.md) | [12.1](/filings/0001437749-25-026967.md) | [9.8](/filings/0001437749-25-034827.md) | [7.3](/filings/0001437749-26-027358.md) | [6.1](/filings/0001437749-26-016762.md) | [5.9](/filings/0001437749-26-027358.md) |
| Short-term borrowings | $m | [0.2](/filings/0001437749-23-031973.md) | [0.0](/filings/0001437749-25-010791.md) | [0.3](/filings/0001437749-24-016366.md) | [0.2](/filings/0001437749-24-026571.md) | [0.1](/filings/0001437749-24-035375.md) | [0.5](/filings/0001437749-26-010126.md) | [0.2](/filings/0001437749-25-017191.md) | [0.1](/filings/0001437749-25-026967.md) | [0.0](/filings/0001437749-25-034827.md) | [0.4](/filings/0001437749-26-027358.md) | [0.2](/filings/0001437749-26-016762.md) | [0.1](/filings/0001437749-26-027358.md) |
| Shareholders' equity | $m | [(12.8)](/filings/0001437749-24-035375.md) | [5.7](/filings/0001437749-26-010126.md) | [(1.3)](/filings/0001437749-25-026967.md) | [(6.0)](/filings/0001437749-25-034827.md) | [(10.0)](/filings/0001437749-25-034827.md) | [0.8](/filings/0001437749-26-027358.md) | [(4.5)](/filings/0001437749-26-027358.md) | [(0.5)](/filings/0001437749-26-027358.md) | [4.5](/filings/0001437749-25-034827.md) | [8.6](/filings/0001437749-26-027358.md) | [17.4](/filings/0001437749-26-027358.md) | [15.2](/filings/0001437749-26-027358.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(6.2) d](/filings/0001437749-24-035375.md) | [(8.9) d](/filings/0001437749-25-010791.md) | [(11.7)](/filings/0001437749-25-017191.md) | [(8.5) d](/filings/0001437749-25-026967.md) | [(4.2) d](/filings/0001437749-25-034827.md) | [(9.1) d](/filings/0001437749-26-010126.md) | [(8.2)](/filings/0001437749-26-016762.md) | [(5.0) d](/filings/0001437749-26-027358.md) | [(5.6) d](/filings/0001437749-25-034827.md) | [(5.8) d](/filings/0001437749-26-010126.md) | [(3.8)](/filings/0001437749-26-016762.md) | [(2.1) d](/filings/0001437749-26-027358.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

Shares outstanding: 13,110,377 at 2026-08-13, from the cover of the [10-Q filed 2026-08-12](/filings/0001437749-26-027358.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.